Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Atomic Pharmaceutics Inc. is currently active in the Biotechnology & Pharmaceuticals technology area with 1 pending office action. This action is assigned to 1 distinct examiner, indicating a focused approach to its current patent filings. The portfolio is also limited to 1 distinct art unit, which suggests that the company's technical focus is highly specialized within the pharmaceutical field. This concentration simplifies the company's interactions with the USPTO. The data shows a very contained prosecution footprint for the company at this time.
The busiest examiner for the company is KETCHAM, KAREN A, who is managing 1 pending office action. This single action represents the total pending workload for the company. With only 1 distinct examiner and 1 distinct art unit involved, the company's immediate patent strategy is centralized. Practitioners should note that the outcome of the company's current patenting efforts depends entirely on the prosecution of this single matter before this specific examiner. This centralized structure allows for a direct and efficient management of the company's intellectual property goals.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KETCHAM, KAREN A | 1 | 19.6% | +37.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18205308 | UNITARY ORAL DOSAGE FORM IN BASE OF SPHERICAL AND/OR SPHEROIDAL SHAPED PARTICLES | KETCHAM, KAREN A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18205308 | UNITARY ORAL DOSAGE FORM IN BASE OF SPHERICAL AND/OR SPHEROIDAL SHAPED PARTICLES | KETCHAM, KAREN A | — |
| Art Unit | Apps |
|---|---|
| 1614 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18205308 | UNITARY ORAL DOSAGE FORM IN BASE OF SPHERICAL AND/OR SPHEROIDAL SHAPED PARTICLES | KETCHAM, KAREN A | 1614 | §103 | Non-Final OA | — | Pending | Jun 02, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAtomic Pharmaceutics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Karen A Ketcham has the most, with 1 of Atomic Pharmaceutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
